The evolution of iron chelators for the treatment of iron overload disease and cancer

Pharmacological Reviews

Volumn 57, Issue 4, 2005, Pages 547-583

  Kalinowski, Danuta S ^a   Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; HEME; IRON CHELATING AGENT; IRON REGULATORY FACTOR; PYRIDINE DERIVATIVE; SIDEROPHORE; THIOSEMICARBAZONE DERIVATIVE;

BETA THALASSEMIA; CANCER THERAPY; DRUG STRUCTURE; FENTON REACTION; FRIEDREICH ATAXIA; HEME SYNTHESIS; HUMAN; HYDROGEN BOND; IRON ABSORPTION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LIPID SOLUBILITY; MOLECULAR INTERACTION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; NEOPLASMS;

EID: 29844457587     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.57.4.2     Document Type: Review

References (258)

1. Abboud S and Haile DJ (2000) A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275:19906-19912.
2. Abeysinghe RD, Greene BT, Haynes R, Willingham MC, Turner J, Planalp RP, Brechbiel MW, Torti FM, and Torti SV (2001) p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2:1607-1614.
3. Agrawal KC and Sartorelli AC (1978) The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog Med Chem 15:321-356.
4. Alper G and Narayanan V (2003) Friedreich's ataxia. Pediatr Neurol 28:335-341.
5. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, and Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360:516-520.
6. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986-1995.
7. Antholine W, Knight J, Whelan H, and Petering DH (1977) Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol Pharmacol 13:89-98.
8. Aouad F, Florence A, Zhang Y, Collins F, Henry C, Ward RJ, and Crichton RR (2002) Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta 339:470-480.
9. Armstrong CM, Bernhardt PV, Chin P, and Richardson DR (2003) Structural variations and formation constants of first-row transition metal complexes of biologically active aroylhydrazones. Eur J Inorg Chem 1145-1156.
10. Avramovici-Grisaru S, Sarel S, Cohen S, and Bauminger RE (1985) The synthesis, crystal and molecular structure and oxidation state of iron complex from pyridoxal isonicotinoyl hydrazone and ferrous sulfate. Israel J Chem 25:288-292.
11. Baker E, Richardson DR, Gross S, and Ponka P (1992b) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:492-501.
12. Baker E, Vitolo ML, and Webb J (1985) Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 34:3011-3017.
13. Baker E, Wong A, Peter H, and Jacobs A (1992a) Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. Br J Haematol 81:424-431.
14. Balfour JAB and Foster RH (1999) Deferiprone: a review of its clinical potential in iron overload in β-thalassemia major and other transfusion-dependent disease. Drugs 58:553-578.
15. Balveer K, Pyar K, and Wonke B (2000) Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia 55:493-497.
16. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, and Watabe K (2003) The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 63:1731-1736.
17. Barnham KJ, Masters CL, and Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3:205-214.
18. Becker E and Richardson DR (1999) Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 134:510-521.
19. Becker E and Richardson DR (2001) Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol 33:1-10.
20. Becker EM, Greer JM, Ponka P, and Richardson DR (2002) Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood 99:3813-3822.
21. Becker EM, Lovejoy DB, Greer JM, Watts RN, and Richardson DR (2003) Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol 138:819-830.
22. Bergeron RJ, Huang G, Smith RE, Bhart N, McManis JS, and Butler A (2003a) Total synthesis and structure revision of petrobactin. Tetrahedron 59:2007-2014.
23. Bergeron RJ, Huang G, Weimar WR, Smith RE, Wiegand J, and McManis JS (2003b) Desferrithiocin analogue based hexacoordinate iron(III) chelators. J Med Chem 46:16-24.
24. Bergeron RJ, Liu CZ, McManis JS, Xia MXB, Algee SE, and Wiegand J (1994) The desferrithiocin pharmacophore. J Med Chem 37:1411-1417.
25. Bergeron RJ, Streiff RR, Creary EA, Daniels RD Jr, King W, Luchetta G, Wiegand J, Moerker T and Peter HH (1993) A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 81:2166-2173.
26. Bergeron RJ, Streiff RR, Wiegand J, Luchetta G, Creary EA, and Peter HH (1992) A comparison of the iron-clearing properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one and deferoxamine. Blood 79:1882-1890.
27. Bergeron RJ, Wiegand J, Dionis JB, Egli-Karmakka M, Frei J, Huxley-Tencer A, and Peter HH (1991) Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J Med Chem 34:2072-2078.
28. Bergeron RJ, Wiegand J, McManis JS, Bussenius J, Smith RE, and Weimar WR (2003c) Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency. J Med Chem 46:1470-1477.
29. Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, and Smith RE (1999a) Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J Med Chem 42:2432-2440.
30. Bergeron RJ, Wiegand J, McManis JS, Weimar WR, and Huang G (2002) Structure-activity relationships among desazadesferrithiocin analogues. Adv Exp Med Biol 509:167-184.
31. Bergeron RJ, Wiegand J, Weimar WR, McManis JS, Smith RE, and Abboud KA (2003d) Iron chelation promoted by desazadesferrithiocin analogs: an enantioselective barrier. Chirality 15:593-599.
32. Bergeron RJ, Wiegand J, Weimar WR, Vinson JRT, Bussenius J, Yao GW, and McManis JS (1999b) Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. J Med Chem 42:95-108.
33. Bergeron RJ, Wiegand J, Wollenweber M, McManis JS, Algee SE, and Ratliff-Thompson K (1996) Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators. J Med Chem 39:1575-1581.
34. Bernhardt PV, Caldwell LM, Chaston TB, Chin P, and Richardson DR (2003) Cytotoxic iron chelators: characterisation of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J Biol Inorg Chem 8:866-880.
35. Bernhardt PV, Chin P, and Richardson DR (2001) Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J Biol Inorg Chem 6:801-809.
36. Bernhardt PV, Chin P, and Richardson DR (2004) Iron catalysed assembly of an asymmetric mixed-ligand triple helicate. Dalton Trans 3342-3346.
37. Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, and Goldman JM (1992) p53 in chronic myeloid leukemia cell lines. Leukemia 6:839-842.
38. Blaha K, Cikrt M, Nerudova J, Fornuskova H, and Ponka P (1998) Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 11:4368-4372.
39. Blatt J and Stitely S (1987) Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res 47:1749-1750.
40. Blatt J, Taylor SR, and Stitely S (1988) Mechanism of antineuroblastoma activity of deferoxamine in vitro. J Lab Clin Med 112:433-436.
41. Brittenham GM (1990) Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol 27:112-116.
42. Brittenham GM (2003) Iron chelators and iron toxicity. Alcohol 30:151-158.
43. Brock JH and Stevenson J (1987) Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator. Immunol Lett 15:23-25.
44. Buss JL, Arduini E, and Ponka P (2002a) Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochem Pharmacol 64:1689-1701.
45. Buss JL, Arduini E, Shephard KC, and Ponka P (2003a) Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. Biochem Pharmacol 65:349-360.
46. Buss JL, Greene BT, Turner J, Torti FM, and Torti SV (2004a) Iron chelators in cancer chemotherapy. Curr Top Med Chem 4:1623-1635.
47. Buss JL, Hermes-Lima M, and Ponka P (2002b) Pyridoxal isonicotinoyl hydrazone and its analogues. Adv Exp Med Biol 509:205-229.
48. Buss JL, Neuzil J, Gellert N, Weber C, and Ponka P (2003b) Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their ironchelating properties. Biochem Pharmacol 65:161-172.
49. Buss JL, Neuzil J, and Ponka P (2002c) The role of oxidative stress in the toxicity of pyridoxal isonicotinoyl hydrazone (PIH) analogues. Biochem Soc Trans 30:755-757.
50. Buss JL, Neuzil J, and Ponka P (2004b) Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs. Arch Biochem Biophys 421:1-9.
51. Buss JL, Torti FM, and Torti SV (2003c) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021-1034.
52. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (Wash DC) 271:1423-1427.
53. Cao A (1995) Molecular basis of β-thalassemia. Bull Mol Biol Med 20:102-112.
54. Chaston TB, Lovejoy DB, Watts RN, and Richardson DR (2003) Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of Triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9:402-414.
55. Chaston TB and Richardson DR (2003a) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity and toxicity. Am J Hematol 73:200-210.
56. Chaston TB and Richardson DR (2003b) Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease. J Biol Inorg Chem 8:427-438.
57. Chaston TB, Watts RN, Yuan J, and Richardson DR (2004) Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves Fenton-derived free radical generation. Clin Cancer Res 10:7365-7374.
58. Chen CH, King I, and Belcourt M (2002) Triapine, a ribonucleotide reductase inhibitor, enhances incorporation of gemcitabine into DNA and cytotoxicity to KB cells. Eur J Cancer 38:S26.
59. Chen H, Attieh ZK, Su T, Syed BA, Gao H, Alaeddine RM, Fox TC, Usta J, Naylor CE, Evans RW, et al. (2004) Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. Blood 103:3933-3939.
60. Cheng Y, Zak O, Aisen P, Harrison SC, and Walz T (2004) Structure of the human transferrin receptor-transferrin complex. Cell 116:565-576.
61. Chong HS, Torti SV, Ma R, Torti FM, and Brechbiel MW (2004) Synthesis and potent antitumor activities of novel 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives. J Med Chem 47:5230-5234.
62. Choudhury R, Epemolu RO, Rai BL, Hider RC, and Singh S (1997) Metabolism and pharmacokinetics of 1-(2′-trimethylacetoxyethyl)-2-ethyl-3- hydroxypyridin-4-one (CP117) in the rat. Drug Metab Dispos 25:332-339.
63. Cikrt M, Ponka P, Necas E, and Neuwirt J (1980) Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol 45:275-283.
64. Cohen SM, O'Sullivan B, and Raymond KN (2000) Mixed hydroxypyridinonate ligands as iron chelators. Inorg Chem 39:4339-4346.
65. Conrad ME and Umbreit JN (2002) Pathways of iron absorption. Blood Cells Mol Dis 29:336-355.
66. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, and Porter JB (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291-20299.
67. 10 therapy. BioFactors 18:163-171.
68. Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, and Sartorelli AC (1994) Inhibitors of ribonucleotide reductase: comparative effects of amino- and hydroxysubstituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 48:335-344.
69. Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, and Enright H (1998) The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 92:632-638.
70. Creasey WA, Agrawal KC, Capizzi RL, Stinson KK, and Sartorelli AC (1972) Antineoplastic activity and metabolism of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res 32:565-572.
71. Darnell G and Richardson DR (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94:781-792.
72. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, and Marks JR (1992) Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7:127-133.
73. Dayani PN, Bishop MC, Black K, and Zeltzer PM (2004) Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 67:367-377.
74. DeConti RC, Toftness BR, Agrawal KC, Tomchick R, Mead JA, Betino JR, Sartorelli AC, and Creasey WA (1972) Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res 32:1455-1462.
75. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, and Helson L (1990) Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50:4929-4930.
76. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, et al. (2000) Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature (Lond) 403:776-781.
77. Dragsten PR, Hallaway PE, Hanson GJ, Berger AE, Bernard B, and Hedlund BE (2000) First human studies with a high-molecular-weight iron chelator. J Lab Clin Med 135:57-65.
78. Dubois JE, Fakhrayan H, Doucet JP, and El Hage Chahine JM (1992) Kinetic and thermodynamic study of complex formation between iron(II) and pyridoxal isonicotinoylhydrazone and other synthetic chelating agents. Inorg Chem 31:853-859.
79. Edward JT, Gauthier M, Chubb FL, and Ponka P (1988) Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data 33:538-540.
80. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Volelstein B (1993) WAF1, a protein mediator of p53 tumor suppression. Cell 75:817-825.
81. Elford HL, Freese M, Passamani E, and Morris HP (1970) Ribonucleotide reductase and cell proliferation. J Biol Chem 245:5228-5233.
82. Finch RA, Liu MC, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng YC, and Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59:983-991.
83. Fleming MD, Trenor CC, Su MA, Foernzler D, Beier DR, Dietrich WF, and Andrews NC (1997) Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 16:383-386.
84. Forsbeck K, Bjelkenkrantz K, and Nilsson K (1986) Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: effects of suramin and a lipophilic iron chelator (PIH). Scand J Haematol 37:429-437.
85. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, and Aprili G (2000) Safety and efficacy of subcutaneous bolus injection deferoxamine in adult patients with iron overload. Blood 95:2776-2779.
86. Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783-788.
87. Gao J and Richardson DR (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 98:842-850.
88. 2O. Inorg Chim Acta 333:132-137.
89. Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, et al. (2003) Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27:1077-1083.
90. Gobin J and Horwitz MA (1996) Exochelins of Mycobacterium tuberculosis remove iron for human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Exp Med 183:1527-1532.
91. Green DA, Antholine WE, Wong SJ, Richardson DR, and Chitambar CR (2001) Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res 11:2574-2579.
92. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, and Sadler PJ (1989) Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis: characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 264:4417-4422.
93. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, and Hediger MA (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature (Lond) 388:482-488.
94. Gutteridge JMC, Rowley DA, Griffiths E, and Halliwell B (1985) Low-molecularweight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 68:463-467.
95. Halliwell B and Gutteridge JMC (1986) Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246:501-514.
96. Halliwell B and Gutteridge JMC (1989) Free Radicals in Biology and Medicine. Claredon Press, Oxford.
97. Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
98. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivary RTA, and Gitlin JD (1995) Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 92:2539-2543.
99. Harrison PM and Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161-203.
100. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, and Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572.
101. Heinz U, Hegetschweiler H, Acklin P, Faller B, Lattmann R, and Schnebli HP (1999) 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew Chem Int Ed 38:2568-2570.
102. Hentze MW and Kühn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc Natl Acad Sci USA 93:8175-8182.
103. Hentze MW, Muckenthaler MU, and Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285-297.
104. •OH-mediated strand breaks. Free Radic Biol Med 25:875-880.
105. Hershko C, Abrahamov A, Konijn AM, Breuer W, Cabantchik IZ, Pootrakul P, and Link G (2003) Objectives and methods of iron chelation therapy. Bioinorg Chem Appl 1:151-168.
106. Hershko C, Graham G, Bates GW, and Rachmilewitz EA (1978) Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40:255-263.
107. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, and Link G (2001) ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-laded rat heart cells in culture. Blood 97:1115-1122.
108. Hider RC (1995) Potential protection from toxicity by oral iron chelators. Toxicol Lett 82-83:961-967.
109. Hider RC (2002a) Nature of nontransferrin-bound iron. Eur J Clin Investig 32:50-54.
110. Hider RC (2002b) Design of therapeutic chelating agents. Biochem Soc Trans 30:751-754.
111. Hider RC, Choudhury R, Rai BL, Dahkordi LS, and Singh S (1996) Design of orally active iron chelators. Acta Haematol 95:6-12.
112. 3+ values. Transfus Sci 23:201-209.
113. 3, M = Ga, In) of N,N′,N″ -tris(2-pyridylmethyl)-cis-1,3,5-triaminocyclohexane: Preparation and structure. Inorg Chem 36:4600-4603.
114. Hodges YK, Antholine WE, and Horwitz LD (2004) Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins. Biochem Biophys Res Commun 315:595-598.
115. Hoy T, Humphrys J, Jacobs A, Williams A, and Ponka P (1979) Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 43:443-449.
116. Ihnat PM, Vennerstrom JL, and Robinson DH (2000) Synthesis and solution properties of deferoxamine amides. J Pharm Sci 89:1525-1536.
117. Jacobs A (1977) Low molecular weight intracellular iron transport compounds. Blood 50:433-439.
118. Johnson DK, Murphy TB, Rose NJ, Goodwin WH, and Pickart L (1982) Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg Chim Acta 67:159-165.
119. Kaplan J, Jordan I, and Sturrock A (1991) Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem 266:2997-3004.
120. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, and Kattamis C (2003) Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 88:1423-1425.
121. Kauppi B, Nielsen BB, Ramaswamy S, Larsen IK, Thelander M, Thelander L, and Eklund H (1996) The three-dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site than Escherichia coli R2. J Mol Biol 262:706-720.
122. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, and Koeffler HP (2000) Transferrin receptor 2-α supports cell growth in both iron-chelated cultured cells and in vivo. J Biol Chem 275:16618-16625.
123. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, and Koeffler HP (1999) Molecular cloning of transferrin receptor 2. J Biol Chem 274:20826-20832.
124. Kicic A, Chua AC, and Baker E (2001a) Effect of iron chelators on proliferation and iron uptake in hepatoma cells. Cancer 92:3093-3110.
125. Kicic A, Chua AC, and Baker E (2001b) The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents. Anticancer Drug Des 16:195-207.
126. Kicic A, Chua AC, and Baker E (2002) Desferrithiocin is a more potent antineoplastic agent than desferrioxamine. Br J Pharmacol 135:1393-1402.
127. Klausner RD, Ashwell G, Van Renswoude J, Harford JB, and Bridges KR (1983) Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci USA 80:2263-2266.
128. Klimtova I, Simunek T, Mazurova Y, Kaplanova J, Sterba M, Hrdina R, Gersl V, Adamcova M, and Ponka P (2003) A study of potential toxic effects after repeated 10-week administration of a new iron chelator-salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta Medica (Hradec Kralove) 46:163-170.
129. Kolberg M, Strand KR, Graff P, and Andersson KK (2004) Structure, function and mechanism of ribonucleotide reductases. Biochim Biophys Acta 1699:1-34.
130. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, and Cabantchik ZI (1999) The cellular labile iron pool and intracellular ferritin in K562 cells. Blood 94:2128-2134.
131. Kontoghiorghes GJ, Neocleous K, and Kolnagou A (2003) Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 26:553-584.
132. Kontoghiorghes GJ, Pattichis K, Neocleous K, and Kolnagou A (2004) The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 11:2161-2183.
133. Krakoff IH, Etcubanas E, Tan C, Mayer K, Betehune V, and Burchenal JH (1974) Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC-107392), with special reference to its iron-chelating properties. Cancer Chemother Rep 53:207-212.
134. Kwok J and Richardson DR (2002) The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 42:65-78.
135. Lamarche JB, Shapcott D, Cote M, and Lemieux B (1993) Cardiac iron deposits in Friedreich's ataxia, in Handbook of Cerebellar Diseases (Lectenberg R ed) pp 453-457, Marcel Dekker, New York.
136. Le NT and Richardson DR (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603:31-46.
137. CIP1/WAF1, but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis 24:1045-1058.
138. Le NT and Richardson DR (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104:2967-2975.
139. Lee GR, Nacht S, Lukens JN, and Cartwright GE (1968) Iron metabolism in copperdeficient swine. J Clin Investig 47:2058-2069.
140. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
141. Liang S and Richardson DR (2003) The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 24:1601-1614.
142. Lieu PT, Heiskala M, Peterson PA, and Yang Y (2001) The roles of iron in health and disease. Mol Aspects Med 22:1-87.
143. Link G, Ponka P, Konijn AM, Breuer W, Cabantchik I, and Hershko C (2003) Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 101:4172-4179.
144. Liu MC, Lin TS, and Sartorelli AC (1992) Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 35:3672-3677.
145. Liu ZD and Hider RC (2002a) Design of iron chelators with therapeutic application. Coord Chem Rev 232:151-171.
146. Liu ZD and Hider RC (2002b) Design of clinically useful iron(III)-selective chelators. Med Res Rev 22:26-64.
147. 3+ values. Bioorg Med Chem 9:563-573.
148. Lodi R, Rajagopalan B, Bradley JL, Taylor DL, Crilley JG, Hart PE, Blamire AM, Manners D, Styles P, Schapira AHV, et al. (2002) Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives. Free Radic Res 36:461-466.
149. Lovejoy DB and Richardson DR (2000) Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Exp Opin Investig Drugs 9:1257-1270.
150. Lovejoy DB and Richardson DR (2002) Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 100:666-676.
151. Lovejoy DB and Richardson DR (2003) Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Cur Med Chem 10:1035-1049.
152. Ma D, Lu F, Overstreet T, Milenic DE, and Brechbiel MW (2002) Novel chelating agents for potential clinical applications of copper. Nucl Med Biol 29:91-105.
153. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, et al. (2002) Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 28:196-208.
154. McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, et al. (2001) An iron-regulated ferric reductase associated with the absorption of dietary iron. Science (Wash DC) 291:1755-1759.
155. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, et al. (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5:299-309.
156. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, and Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391-3395.
157. Morgan EH (1981) Transferrin biochemistry, physiology and clinical significance. Mol Aspects Med 4:1-123.
158. Motekaitis RJ and Martell AE (1991) Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorg Chim Acta 183:71-80.
159. Muhlenhoff U, Richhardt N, Ristow M, Kispal G, and Lill R (2002) The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 11:2025-2036.
160. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, and Sznol M (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 15:4092-4100.
161. Nakano K, Balint E, Ashcroft M, and Vousdes KH (2000) A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19:4283-4289.
162. Napier I, Ponka P, and Richardson DR (2005) Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 105: 1867-1874.
163. Neilands JB (1995) Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 270:26723-26726.
164. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, and Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (Wash DC) 306:2090-2093.
165. Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, and Alberti D (2003) Development of tridentate iron chelators: from desferrithiocin to ICL670. Cur Med Chem 10:1065-1076.
166. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, and Vaulont S (2001) Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98:8780-8785.
167. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer K, et al. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomized, doubleblind, placebo-controlled, does-escalation trial. Lancet 361:1597-1602.
168. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graeslund A, and Thelander L (1993) Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 268:26200-26205.
169. Olivieri NF and Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739-761.
170. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, and Fleming KA (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New Engl J Med 339:417-422.
171. Oshiro S, Nakajima H, Markello T, Krasnewich D, Bernardini I, and Gahl WA (1993) Redox, transferrin-independent and receptor-mediated endocytosis iron uptake systems in cultured human fibroblasts. J Biol Chem 268:21586-21591.
172. Owen CA Jr (1973) Effects of iron on copper metabolism and copper on iron metabolism in rats. Am J Physiol 224:514-518.
173. Pahl PMB, Horwitz MA, Horwitz KB, and Horwitz LD (2001) Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 69:69-79.
174. Pahl PMB, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, and Horwitz LD (2000) An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem 275:17821-17826.
175. Pandolfo M (2002) Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Blood Cells Mol Dis 29:536-547.
176. Pandolfo M (2003) Friedreich ataxia. Semin Pediatr Neurol 10:163-172.
177. Park G, Lu FH, Ye N, Brechbiel MW, Torti SV, Torti FM, and Planalp RP (1998) Novel iron complexed and chelators based on cis,cis-1,3,5- triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties. J Biol Inorg Chem 3:449-457.
178. 2 (M = Zn, Cd and Hg). Polyhedron 19:1155-1161.
179. Patrick GL (2001) An introduction to Medicinal Chemistry. Oxford University Press, New York.
180. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, and Loreal O (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276:7811-7819.
181. Planalp RP, Przyborowska AM, Park G, Ye N, Lu FH, Rogers RD, Broker GA, Torti SV, and Brechbiel MW (2002) Novel cytotoxic chelators that bind iron(II) selectively over zinc(II) under aqueous aerobic conditions. Biochem Soc Trans 30:758-762.
182. Ponka P (1997) Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89:1-25.
183. Ponka P, Borova J, Neuwirt J, and Fuchs O (1979a) Mobilization of iron from reticulocytes: identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97:317-321.
184. Ponka P, Borova J, Neuwirt J, Fuchs O, and Necas E (1979b) A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586:278-297.
185. Ponka P, Richardson D, Baker E, Schulman HM, and Edward JT (1988) Effect of pyridoxal isonicotinoyl hydrazone (PIH) and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta 967:122-129.
186. Ponka P and Schulman HM (1985) Acquisition of iron from transferrin regulates reticulocytes heme synthesis. J Biol Chem 260:14717-14721.
187. Ponka P, Schulman HM, and Wilczynska A (1982) Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim Biophys Acta 718:151-156.
188. Poreddy AR, Schall OF, Osiek TA, Wheatley JR, Beusen DD, Marshall GR, and Slomczynska U (2004) Hydroxamate-based iron chelators: combinatorial syntheses of desferrioxamine B analogues and evaluation of binding affinities. J Comb Chem 6:239-254.
189. Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, and Hider RC (1990) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76:2389-2396.
190. Porter JB, Singh S, Hoyes KP, Epemolu O, Abeysinghe RD, and Hider RC (1994) Lessons from preclinical and clinical studies with 1,2-diethyl-3- hydroxypyridin-4-one, CP94 and related compounds. Adv Exp Med Biol 356:361-370.
191. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, and Pommier Y (2002) Gemcitabine (2′,2′- difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 8:2499-2504.
192. Puccio H and Koenig M (2000) Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 9:887-892.
193. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, and Koenig M (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27:181-186.
194. Quigley JG, Yang Z, Worthington MT, Phillips JD, Sabo KM, Sabath DE, Berg CL, Sassa S, Wood BL, and Abkowitz JL (2004) Identification of a human heme exporter that is essential for erythropoiesis. Cell 118:757-766.
195. Reid RT, Live DH, Faulkner DJ, and Butler A (1993) A siderophore from a marine bacterium with an exceptional ferric ion affinity constant. Nature (Lond) 366:455-458.
196. Richardson DR (1997) Iron chelators as effective anti-proliferative agents. Can J Physiol Pharmacol 75:164-1180.
197. Richardson DR (1999) The role of ceruloplasmin and ascorbate in cellular iron release. J Lab Clin Med 134:454-465.
198. Richardson DR (2001) The controversial role of deferiprone in the treatment of thalassemia. J Lab Clin Med 137:324-329.
199. Richardson DR (2002) Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42:267-281.
200. Richardson DR (2003) Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Investig Drugs 12:235-245.
201. Richardson DR (2004) Mysteries of the transferrin-transferrin receptor 1 interaction uncovered. Cell 116:483-489.
202. Richardson DR (2005) Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer and other diseases. Curr Med Chem, in press.
203. Richardson DR and Baker E (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim Biophys Acta 1053:1-12.
204. Richardson DR and Baker E (1991) The uptake of inorganic iron complexes by human melanoma cells. Biochim Biophys Acta 1093:20-28.
205. Richardson DR and Baker E (1992) Two mechanisms of iron uptake from transferrin by melanoma cells: the effect of desferrioxamine and ferric ammonium citrate. J Biol Chem 267:13972-13979.
206. Richardson DR, Becker E, and Bernhardt PV (1999) The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2-pyridylcarboxaldehyde benzoylhydrazone monohydrate and 2-furaldehyde isonicotinoylhydrazone. Acta Crystallogr C 55:2102-2105.
207. Richardson DR and Bernhardt PV (1999) Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem 4:266-273.
208. Richardson DR, Hefter GT, May PM, Webb J, and Baker E (1989) Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium( II), magnesium(II) and zinc(II). Biol Met 3:161-167.
209. Richardson DR and Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025-3038.
210. Richardson DR, Mouralian C, Ponka P, and Becker E (2001) Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536:133-140.
211. Richardson DR and Ponka P (1994) The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124:660-671.
212. Richardson DR and Ponka P (1995) Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim Biophys Acta 1269:105-114.
213. Richardson DR and Ponka P (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331:1-40.
214. Richardson DR and Ponka P (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131:306-315.
215. Richardson DR, Ponka P, and Vyoral D (1996) Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 87:3477-3488.
216. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
217. Richardson DR, Vitolo LMW, Hefter GT, Mat PM, Clare BW, Webb J, and Wilairat P (1990) Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionisation characteristics of the ligands and their relevance to biological properties. Inorg Chim Acta 170:165-170.
218. Ristow M, Pfister MF, Yee AJ, Schubert M, Michael L, Zhang CY, Ueki K, Michael MD 2nd, Lowell BB, and Kahn CR (2000) Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci USA 97:12239-12243.
219. Ross DD and Cuddy DP (1994) Molecular effects of 2′,2′- difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48:1619-1630.
220. Rotig A, de Lonlay P, Chreiten D, Foury F, Koenig M, Sidi D, Munnich A, and Rustin P (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17:215-217.
221. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, and Rotig A (1999) Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354:477-479.
222. Sachez-Casis G, Cote M, and Barbeau A (1976) Pathology of the heart in Friedreich's ataxia. Can J Neurol Sci 3:349-354.
223. Samuni AM, Krishna MC, DeGraff W, Russo A, Planalp RP, Brechbiels MW, and Mitchell JB (2003) Mechanisms underlying the cytotoxic effects of Tachpyr - a novel metal chelator. Biochim Biophys Acta 1571:211-218.
224. Sartorelli AC, Agrawal KC, and Moore EC (1971) Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem Pharmacol 20:3119-3123.
225. Sartorelli AC and Booth BA (1967) Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis(thiosemicarbazone). Cancer Res 27:1614-1619.
226. Schrier SL, Centis F, Verneris M, Ma L, and Angelucci E (2003) The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep 8:241-245.
227. Sergejew T, Forgiarini P, and Schnebli HP (2000) Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol 110:985-992.
228. Shao J, Zhou B, Zhu L, Qui W, Yuan YC, Xi B, and Yen Y (2004) In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 64:1-6.
229. Shinar E and Rachmilewitz EA (1990) Oxidative denaturation of red blood cells in thalassemia. Semin Hematol 27:70-82.
230. Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, and Hider RC (1992) Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos 20:256-261.
231. Streater M, Taylor PD, Hider RC, and Porter J (1990) Novel 3-hydroxy-2(1H)-pyridinones: synthesis, iron(III)-chelating properties and biological activity. J Med Chem 33:1749-1755.
232. Sturrock A, Alexander J, Lamb J, Craven CM, and Kaplan J (1990) Characterization of a transferrin-independent uptake system for iron in HeLa cells. J Biol Chem 265:3139-3145.
233. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, and Spino M (2003) Iron chelator research: past, present and future. Cur Med Chem 10:983-995.
234. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (Lond) 404:42-49.
235. Thelander L and Gräslund A (1983) Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. J Biol Chem 258:4063-4066.
236. Thelander L, Gräslund A, and Thelander M (1983) Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun 110:859-865.
237. Thelander L and Reichard P (1979) The reduction of ribonucleotides. Annu Rev Biochem 48:133-158.
238. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, and Planalp RP (1998) Tumor cell cytotoxicity of a novel metal chelator. Blood 92:1384-1389.
239. Trinder D, Zak O, and Aisen P (1996) Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology 23:1512-1520.
240. Uc A, Stokes JB, and Britigan BE (2004) Heme transport exhibits polarity in Caco-2 cells: evidence for an active and membrane protein-mediated process. Am J Physiol 287:G1150-G1157.
241. Vaughn CB, Weinstein R, Bond B, Rice R, Vaughn RW, McKendrick A, Ayad G, Rockwell MA, and Rocchio R (1987) Ferritin content in human cancerous and noncancerous colonic tissue. Cancer Investig 5:7-10.
242. Vitolo LMW, Hefter GT, Clare BW, and Webb J (1990) Iron chelators of the pyridoxal isonictinoyl hydrazone class. Part II. Formation constants with iron(III) and iron( II). Inorg Chim Acta 170:171-176.
243. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, and Anderson GJ (1999) Hephaestin, a ceruloplasmin homolog implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21:195-199.
244. Vyoral D, Hradilek A, and Neuwirt J (1992) Transferrin and iron distribution in subcellular fractions of K562 cells in the early stages of transferrin endocytosis. Biochim Biophys Acta 137:148-154.
245. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, and Sznol M (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22:1553-1563.
246. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, and Cohen AR (2002) Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent betathalassemia. Blood 100:1566-1569.
247. Watts RN, Ponka P, and Richardson DR (2003) Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. Biochem J 369:429-440.
248. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F, and Cortopassi G (1999) The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8:425-430.
249. Wong C and Richardson DR (2003) β-Thalassaemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 35:1144-1149.
250. Wong CSM, Kwok JC, and Richardson DR (2004) PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim Biophys Acta 1739:70-80.
251. Xu J, O'Sullivan B, and Raymond KN (2002) Hexadentate hydroxypyridonate iron chelators based on TREN-Me-3,2-HOPO: variation of cap size. Inorg Chem 41:6731-6742.
252. Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, and Sznol M (2004) A phase I trial of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54:331-342.
253. Yokel RA, Fredenburg AM, Durbin PW, Xu J, Rayens MK, and Raymond KN (2000) The hexadentate hydroxypyridinoate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue. J Pharm Sci 89:545-555.
254. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458.
255. Zanninelli G, Choudhury R, Loreal O, Guyader D, Lescoat G, Arnaud J, Verna R, Cosson B, Singh S, Hider RC, and Brissot P (1997) Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma nontransferrin-bound iron in rats. J Hepatol 27:176-184.
256. Zeng YX and El-Deiry WS (1996) Regulation of p21 WAF1/CIP1 expression by p53-independent pathways. Oncogene 12:1557-1564.
257. Zhang AS, Sheftel AD, and Ponka P (2005) Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 105:368-375.
258. Zhao R, Planalp RP, Ma R, Greene BT, Jones BT, Brechbiel MW, Torti FM, and Torti SV (2004) Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol 67:1677-1688.